Together with the finding that cytoplasmic clusterin expression is associated with chemoresistance [32], it is presumed that clusterin is basically cytoprotective and favorably affects prognosis in early stage lung cancer but compromises prognosis during late stage disease by conferring resistance to adjuvant radiotherapy and chemotherapy [33]. The gene discussed is CLU; the disease is lung carcinoma.